Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | E4412 update: ipi-nivo-brentuximab for R/R Hodgkin lymphoma

Catherine Diefenbach • 19 Jun 2019
ICML 2019
Hodgkin Lymphoma Lymphoma Brentuximab vedotin Checkpoint inhibitors Ipilimumab Nivolumab
E4412

Catherine Diefenbach, MD, NYU Langone, New York, NY, gives an update on the extended follow-up of the E4412 trial (NCT01896999), which investigated the combination of ipilimumab, nivolumab and brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Catherine Diefenbach

A Phase Ib study of venetoclax plus Pola-R-CHP in the frontline for patients with DLBCL 2:41
A Phase Ib study of venetoclax plus Pola-R-CHP in the frontline for patients with DLBCL
Catherine Diefenbach • 7 Dec 2024
Glofitamab plus R-ICE chemotherapy in R/R DLBCL: a Phase Ib study 3:31
Glofitamab plus R-ICE chemotherapy in R/R DLBCL: a Phase Ib study
Catherine Diefenbach • 7 Dec 2024
A study of brentuximab vedotin, nivolumab, and ipilimumab in pediatric patients with R/R cHL 1:49
A study of brentuximab vedotin, nivolumab, and ipilimumab in pediatric patients with R/R cHL
Catherine Diefenbach • 7 Dec 2024
Brentuximab vedotin with nivolumab ± ipilimumab in R/R HL: outcomes with and without autoSCT 6:45
Brentuximab vedotin with nivolumab ± ipilimumab in R/R HL: outcomes with and without autoSCT
Catherine Diefenbach • 11 Dec 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals